Advertisement

Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum

  • Maurizio Battaglia Parodi
  • Francesco Romano
  • Alessandro MarcheseEmail author
  • Alessandro Arrigo
  • Victor Llorenç
  • Maria Vittoria Cicinelli
  • Francesco Bandello
  • Alfredo Adán
Retinal Disorders

Abstract

Purpose

To evaluate the efficacy of intravitreal anti-VEGF injections in choroidal neovascularization (CNV) related to pattern dystrophy-like deposit in pseudoxanthoma elasticum (PXE).

Methods

One-year prospective, interventional study. Nine eyes were recruited in the ophthalmology departments of San Raffaele University and University of Barcelona. Each patient underwent best corrected visual acuity (BCVA) measurement on ETDRS chart, slit-lamp biomicroscopy, fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT). The protocol included a first anti-VEGF injection, followed by monthly evaluations with re-treatments based on new funduscopic hemorrhages, fluid on OCT or leakage on FA and/or ICGA. Primary outcome measures were the mean BCVA changes. Secondary outcomes included central macular thickness (CMT) variations and the number of injections needed.

Results

At month 12, mean BCVA significantly improved from 20/45 to 20/35 Snellen equivalent, with 3 eyes gaining at least 3 ETDRS lines. Mean CMT decreased from 297 ± 22 to 262 ± 13 μm, after 5.5 ± 4.0 injections. No leakage was observed at the end of follow-up.

Conclusions

Intravitreal anti-VEGF injections represent an effective treatment for CNV related to pattern dystrophy-like deposit in PXE, with an improvement of BCVA and CMT. Mean injection number is in line with other studies performed in CNV secondary to angioid streaks.

Keywords

Choroidal neovascularization CNV Pattern dystrophy Pseudoxanthoma elasticum PXE Anti-VEGF Multimodal imaging 

Notes

Compliance with ethical standards

Conflict of interest

Battaglia Parodi M has the following financial disclosures: Bausch & Lomb Inc. (C). Bandello F has the following financial disclosures: Alcon (C), Allergan Plc.(C), Famila-Thea (C), Bayer Schering Pharma AG (C), Bausch & Lomb (C), Hoffmann-La-Roche (C), Novartis (C), Sanofi-Aventis (C), and Carl Zeiss AG (C). FR, AM, AA, and MVC have no financial disclosures. Llorenç V has the following financial disclosures: Abbvie (G, C), Allergan(C), UCB(C). Adan A has the following financial disclosures: Abbvie (G, C), Allergan (G, C), UCB(C).

Ethical approval

The research was approved by the local Institutional Review Board and adhered to the tenets of the Declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Uitto J, Bercovitch L, Terry SF, Terry PF (2011) Pseudoxanthoma elasticum: progress in diagnostics and research towards treatment: summary of the 2010 PXE International Research Meeting. Am J Med Genet A 155A:1517–1526CrossRefGoogle Scholar
  2. 2.
    Agarwal A, Patel P, Adkins T, Gass JD (2005) Spectrum of pattern dystrophy in pseudoxanthoma elasticum. Arch Ophthalmol 123:923–928CrossRefGoogle Scholar
  3. 3.
    Battaglia Parodi MB, Iacono P, Bandello F (2015) Pseudoxanthoma elasticum associated with vitelliform macular lesion. Ophthalmic Surg Lasers Imaging Retina 46:287–288CrossRefGoogle Scholar
  4. 4.
    Battaglia Parodi M, Casalino G, Iacono P, Introini U, Adamyan T, Bandello F (2017) The expanding clinical spectrum of choroidal excavation in macular dystrophies. Retina.  https://doi.org/10.1097/IAE.0000000000001805 CrossRefGoogle Scholar
  5. 5.
    Clarkson JG, Altman RD (1982) Angioid streaks. Surv Ophthalmol 26:235–246CrossRefGoogle Scholar
  6. 6.
    Lim JI, Bressler NM, Marsh MJ, Bressler SB (1993) Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 116:414–423CrossRefGoogle Scholar
  7. 7.
    Pece A, Avanza P, Galli L, Brancato R (1997) Laser photocoagulation of choroidal neovascularization in angioid streaks. Retina 17:12–16CrossRefGoogle Scholar
  8. 8.
    Wiegand TW, Rogers AH, McCabe F, Reichel E, Duker JS (2009) Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularization in patients with angioid streaks. Br J Ophthalmol 93:47–51CrossRefGoogle Scholar
  9. 9.
    Da Pozzo S, Battaglia Parodi M, Toto L, Ravalico G (2001) Occult choroidal neovascularization in adult-onset foveomacular vitelliform dystrophy. Ophthalmologica 215:412–414CrossRefGoogle Scholar
  10. 10.
    Zweifel SA, Imamura Y, Freund KB, Spaide RF (2011) Multimodal fundus imaging of pseudoxanthoma elasticum. Retina 31:482–491CrossRefGoogle Scholar
  11. 11.
    Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P (2013) An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet 4:14CrossRefGoogle Scholar
  12. 12.
    Tilleul J, Mimoun G, Querques G et al (2016) Intravitreal ranibizumab for choroidal neovascularization in angioid streaks: four-year follow-up. Retina 36:483–491CrossRefGoogle Scholar
  13. 13.
    Alagöz C, Alagöz N, Özkaya A et al (2015) Intravitreal bevacizumab in the treatment of choroidal neovascular membrane due to angioid streaks. Retina 35:2001–2010CrossRefGoogle Scholar
  14. 14.
    Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P (2013) Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina 33:1300–1314CrossRefGoogle Scholar
  15. 15.
    Shah M, Amoaku WM (2012) Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks. Eye (Lond) 26:1194–1198CrossRefGoogle Scholar
  16. 16.
    Finger RP, Charbel Issa P, Hendig D, Scholl HP, Holz FG (2011) Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study. Am J Ophthalmol 152:695–703CrossRefGoogle Scholar
  17. 17.
    El Matri L, Kort F, Bouraoui R, Karim B, Chebil A, Chaker N (2011) Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up. Acta Ophthalmol 89:641–646CrossRefGoogle Scholar
  18. 18.
    Teixeira A, Mattos T, Velletri R et al (2010) Clinical course of choroidal neovascularization secondary to angioid streaks treated with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 41:546–549CrossRefGoogle Scholar
  19. 19.
    Mimoun G, Tilleul J, Leys A, Coscas G, Soubrane G, Souied EH (2010) Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Am J Ophthalmol 150:692–700CrossRefGoogle Scholar
  20. 20.
    Iacono P, Battaglia Parodi M, La Spina C, Bandello F (2016) Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks: 3-year follow-up study. Am J Ophthalmol 165:174–178CrossRefGoogle Scholar
  21. 21.
    Battaglia Parodi M, Iacono P, La Spina C et al (2014) Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks. Am J Ophthalmol 157:374–377CrossRefGoogle Scholar
  22. 22.
    Vaclavik V, Tran HV, Gaillard MC, Schorderet DF, Munier FL (2012) Pattern dystrophy with high intrafamilial variability associated with Y141C mutation in the peripherin/RDS gene and successful treatment of subfoveal CNV related to multifocal pattern type with anti-VEGF (ranibizumab) intravitreal injections. Retina 32:1942–1949CrossRefGoogle Scholar
  23. 23.
    Battaglia Parodi M, Iacono P, Cascavilla M, Zucchiatti I, Kontadakis DS, Bandello F (2010) Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Invest Ophthalmol Vis Sci 51:4358–4361CrossRefGoogle Scholar
  24. 24.
    Battaglia Parodi M, Di Crecchio L, Ravalico G (2000) Vascularized pigment epithelial detachment in adult-onset foveomacular vitelliform dystrophy. Eur J Ophthalmol 10:266–269CrossRefGoogle Scholar
  25. 25.
    Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Maurizio Battaglia Parodi
    • 1
  • Francesco Romano
    • 1
  • Alessandro Marchese
    • 1
    Email author return OK on get
  • Alessandro Arrigo
    • 1
  • Victor Llorenç
    • 2
  • Maria Vittoria Cicinelli
    • 1
  • Francesco Bandello
    • 1
  • Alfredo Adán
    • 2
  1. 1.Department of Ophthalmology, Scientific Institute San RaffaeleUniversity Vita-SaluteMilanItaly
  2. 2.Institut Clínic d’OftalmologiaHospital Clínic de BarcelonaBarcelonaSpain

Personalised recommendations